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RESEARCH TOPIC
A. Study Of Fibrinolysis
According to present concepts, the enzyme 
responsible for the dissolution of fibrin both 
intra - and extra - vascularly is generated by 
the action of an “ activator”  upon the enzyme 
precursor plasminogen. Plasminogen is a B  - 
globulin, of molecular weight of the order of 
143,000, and a normal constituent of human 
plasma. It is known to possess a high affinity 
for both fibrin and fibrinogen, a property 
fundam ental to the Sherry hypothesis of the 
physiological function of plasminogen where 
any fibrin clot is visualised as having an in­
trinsic plasminogen content sufficient to ensure 
its lysis when activated. T h e  activation is 
achieved by activator either trapped within the 
clot at the mom ent of polymerisation, or diffus­
ing subsequently into the clot from the sur­
rounding liquid phase.
Abundant evidence now exists to suggest 
that plasminogen activator is released locally 
by blood vessels into the circulation in response 
to acute vascular changes(1A3) In a series of 
straightforward “ in vitro”  experiments in which 
tissue slices were placed upon a layer of pre­
formed fibrin and local areas of fibrinolysis 
related to overlying anatomical structures, 
T o d d (4) presented evidence which suggests that 
the human vascular endothelium serves as a 
labile pool for this activator. However, so far 
the majority of studies on fibrinolytic pheno­
mena “ in vivo”  have been conducted with 
regard to the general circulation; thus it has 
been demonstrated that in normal subjects 
systemic levels of circulating activator will 
increase substantially in response to various 
physiological stimuli, notably exercise (5) and 
mental stress.
An intriguing question arises as to the gross 
anatomical origins of all this activator, and in 
an attem pt to elucidate such a source I em- 
barked, in the summer of 1966, upon an 
investigation of the human uterus(6).
T h e subjects were fifteen fem ale patients 
undergoing surgery involving lower abdominal 
incisions. Blood samples were taken from the 
uterine artery, uterine vein, and for control 
purposes from a vein in the cubital fossa. The
majority of the plasma so obtained was treated 
with acetic acid to precipitate the euglobulin 
fraction. T h is moiety is relatively free from 
plasmin inhibitors, which “ in vivo”  are ex­
cluded from formed clots, but which are 
present in plasma. T h e remainder was used for 
inhibitor estimations.
A  proportion of the euglobulin was clotted 
and incubated at 37 °C ., and the tim e taken 
for the spontaneous lysis of the euglobulin 
clot was taken as a measure of activator con­
centration. Other aliquots were used for the 
estimations of plasminogen and fibrinogen 
levels. Parallel measurements of fibrin degrad­
ation products (F .D .P .), the result of “ in vivo”  
plasmin activity in the subject, were carried out 
using a technique in which inhibition of anti- 
serum agglutination of fibrinogen —  coated 
red blood cells by these F .D .P .'s  —  bears a 
quantitative relationship to their concentration.
It was found that the uterine venous samples 
had a significantly (0 .0 0 1< P< 0.002) greater 
content of plasminogen activator than the 
arterial samples. Plasminogen, fibrinogen and 
plasmin inhibitor concentrations bore neither 
qualitative nor quantitative correlation to this 
fibrinolytic activity, there being no significant 
difference in these parameters between venous 
and arterial groups. T h e  arterio - venous com ­
parison of fibrin degradation products showed 
a significantly (P< 0.001) higher concentration 
in the uterine vein than the artery.
These results show that under the conditions 
of the study, the uteri were contributing to the 
fibrinolytic potential of the circulating blood. 
This contribution must be in the form of 
activator, since no com plimentary difference 
in any of the other parameters could account 
for the present findings. T h e  discovery of 
F .D .P .’s com ing from the human uterus makes 
it conceivable that normally a constant con­
sumption of the factors of fibrinolysis is taking 
place, with the enzymatic breakdown of fibrin, 
thus necessitating their continual maintenance.
Experiments on human blood by Buluk & 
Furman (7) in which an arterio - venous 
activator difference was demonstrated across the
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kidney suggested to these authors that the 
kidneys might be the organs responsible for 
activator maintenance. The evidence presented 
above must throw doubt upon any assumption 
that, in females at least, the kidney is the sole 
candidate for this role.
The fact that no significant reduction in 
plasminogen or fibrinogen levels was found on 
passage through the uterus is interesting in 
that active fibrin disintegration can apparently 
proceed without detectable consumption of 
these factors. Such a consumption must be 
real, but the quantities involved are presumably 
below the detection threshold of our present 
techniques, quite apart from being insignificant 
within their total plasma concentrations.
One could say that it is hardly surprising that
an organ so highly vascular and constantly 
involved in the process of coagulation and 
fibrinolysis s h o u ld  b e  f o u n d t o  h ave a 
high activator potential, but when a definite 
contribution by this organ to systemic activator 
levels is evident, one must consider not only 
the local processes involved with menstruation 
and pregnancy, but also the part played by this, 
and conceivably a number of other organs in 
the complex fibrinolytic picture of the body as 
a whole.
In order to further these existing lines of 
thought I hope, this coming summer, to carry 
investigations to dogs, where experimental 
scope is wider.
ANGUS V. P. MACKAY, B.Sc.
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